Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of MD-0901 (once-daily mesalazine) vs Asacol in Ulcerative Colitis
jRCT2080222425Phase 3
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mesalazine in autoimmune colitis (2 arms), sponsored by Mochida Pharmaceutical Co., Ltd.
02
Drugs
mesalazine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080222425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222425.